Figure 2 | Modern Pathology

Figure 2

From: Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation

Figure 2

Survival analysis for ErbB2 in oesophageal adenocarcinomas. (a) ErbB2 and disease-free survival (DFS); (b) ErbB2 and overall survival (OS). ErbB2 positivity is defined as immunohistochemistry 3+ and/or an ErbB2/Chr17 quotient of >2 as assessed by in situ hybridisation.

Back to article page